对于一些既往的热门赛道，比如GLP-1，最终能脱颖而出的仍将会是少数企业，决定因素是临床效果。尚未上市的产品必须要找到差异化优势：一是给药形式优化，不少人都会在意注射带来的疼痛和不便，所以口服剂型仍有空间；二是疗效，特别是减重效果、心血管获益等；三是给药频率，半衰期更长、给药频次更低的产品更有机会；四是长期安全性，降低不良反应，减少停药反弹等。
So that’s one reason to go back and read Bourdieu himself: The neutered version of his ideas that comes out of HR / DEI / PR departments today just doesn’t have the same charm.，这一点在新收录的资料中也有详细论述
。新收录的资料是该领域的重要参考
“It would be weird if the restaurant sold the reservations to the highest bidder,” Kessler said. “That would seem weird—[for] the same reason, like, Taylor Swift doesn’t sell tickets to her tour for $3,000 a piece, because that would seem too high, even though that’s what the secondary market says the prices kind of should be.” The super-popular restaurant could auction off reservations, too, but we think that would be weird too, Kessler added.
在这个过程中，定位的调整比技术路线的切换更为关键。OpenClaw之所以让大厂放心，是因为它不试图成为用户与数字世界之间的唯一中介，只是提供工具，让用户自己决定用谁的模型、部署在谁的云上。豆包如果能将定位从"流量中介"调整为"能力增强层"，主动开放接口、让应用厂商也能从AI调度中获益，封锁的动机自然会弱化。。业内人士推荐新收录的资料作为进阶阅读